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The association of APOE genotype with circulating apolipoprotein E (ApoE) concentration
and cardiovascular disease (CVD) risk is well established. However, the relationship of cir-
culating ApoE concentration and CVD has received little attention.
Methods and Findings
To address this, we measured circulating ApoE concentration in 9,587 individuals (with
1,413 CVD events) from three studies with incident CVD events: two population-based
studies, the English Longitudinal Study of Ageing (ELSA) and the men-only Northwick
Park Heart Study II (NPHSII), and a nested sub-study of the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT). We examined the association of circulating ApoE with cardio-
vascular risk factors in the two population-based studies (ELSA and NPHSII) and the rela-
tionship between ApoE concentration and coronary heart disease and stroke in all three
studies. Analyses were carried out within study, and, where appropriate, pooled effect esti-
mates were derived using meta-analysis. In the population-based samples, circulating
ApoE was associated with systolic blood pressure (correlation coefficient 0.08, p < 0.001,
in both ELSA and NPHSII), total cholesterol (correlation coefficient 0.46 and 0.34 in ELSA
and NPHSII, respectively; both p < 0.001), low-density lipoprotein cholesterol (correlation
coefficient 0.30 and 0.14, respectively; both p < 0.001), high-density lipoprotein (correla-
tion coefficient 0.16 and −0.14, respectively; both p < 0.001), and triglycerides (correlation
coefficient 0.43 and 0.46, respectivly; both p < 0.001). In NPHSII, ApoE concentration was
additionally associated with apolipoprotein B (correlation coefficient 0.13, p = 0.001) and
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lipoprotein(a) (correlation coefficient −0.11, p < 0.001). In the pooled analysis of ASCOT,
ELSA, and NPHSII, there was no association of ApoE with CVD events; the odds ratio
(OR) for CVD events per 1-standard-deviation higher ApoE concentration was 1.02 (95%
CI 0.96, 1.09). After adjustment for cardiovascular risk factors, the OR for CVD per 1-stan-
dard-deviation higher ApoE concentration was 0.97 (95% CI 0.82, 1.15). Limitations of
these analyses include a polyclonal method of ApoE measurement, rather than isoform-
specific measurement, a moderate sample size (although larger than any other study to
our knowledge and with a long lag between ApoE measures), and CVD events that may
attenuate an effect.
Conclusions
In the largest study to date on this question, we found no evidence of an association of cir-
culating ApoE concentration with CVD events. The established association of APOE geno-
type with CVD events may be explained by isoform-specific functions as well as other
mechanisms, rather than circulating concentrations of ApoE.
Author Summary
Why Was This Study Done?
• Heart attacks and strokes, jointly referred to as cardiovascular disease (CVD), are the
most common causes of death worldwide. Identifying risk factors that can be used to
predict these events can be valuable for prevention, and identifyingmolecular pathways
involved in risk can be useful for the development of preventive drugs.
• ApoE is a circulating protein that binds to and may regulate circulating lipoproteins,
which are proteins that combine with and transport lipids and fat in the bloodstream.
ApoE has several genetic variants in the human population; in previous studies, certain
ApoE variants (genotypes) have been shown to be associated with greater risk of CVD.
• One hypothesis is that the amount of ApoE protein circulating in the body, which has
been shown to vary by ApoE genotype, mediates the risk of CVD.
What Did the Researchers Do and Find?
• We measured ApoE concentrations directly in ~10,000 individuals, ~1,400 of whom had
CVD events. We did not find any association of circulating ApoE with CVD, even after
adjusting for other CVD-related factors that might obscure an association.
• We also placed ApoE concentration in the context of clinical risk equations that are used
to assess risk in patients, and found that it did not improve risk prediction.
Circulating ApoE and CVD Risk
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What Do These Findings Mean?
• This study demonstrates that ApoE genotypes that confer risk of CVDmight do so via
protein function rather than protein concentration in the blood.
• ApoE may still be a drug target for prevention of CVD.
Introduction
Apolipoprotein E (ApoE) is a 34-kDa liver-derived multifunctional protein found associated
with triglyceride-rich chylomicrons and very low density lipoproteins (VLDLs), their rem-
nants, and a subset of high-density lipoprotein particles [1,2]. One of ApoE’s major physiologi-
cal roles is in lipid metabolism; ApoE mediates high-affinity binding of ApoE-containing
lipoproteins to the low-density lipoprotein receptor (LDL-R) and LDL receptor related protein
1 (LRP1), facilitating clearance of triglyceride-rich lipoproteins from the circulation. It is this
mechanism that is thought to confer protection from atherogenesis. ApoE is a polymorphic
protein with three major circulating isoforms, E2, E3, and E4 [3], and lipid metabolism is iso-
form dependent. Isoforms are determined by a combination of two common non-synonymous
single nucleotide polymorphisms (SNPs rs7412 and rs429358) in exon 4 of the APOE gene on
Chromosome 19 [4]. The most commonly observed, and the reference, isoform is E3. E3 has a
cysteine residue at 112 and an arginine residue at 158, and is present in ~79% of the population.
E4 (rs429358), the next most commonly encountered isoform (~14%), has an arginine residue
substituting cysteine at 112. Finally, E2 (rs7412) is present at a frequency of ~7% and has a cys-
teine substituting arginine at residue 158. The resultant six common genotypes, in order of
observed frequency, are ε3/ε3, ε3/ε4, ε2/ε3 ε2/ε4, ε4/ε4, and ε2/ε2. The most common geno-
type group is ε3/ε3, which serves as the reference category.
Very low circulating concentration of ApoE in humans is associatedwith early onset athero-
sclerosis [5]. Mice in which the APOE gene is deleted are prone to developing atherosclerosis
[6]. Together, these findings have contributed to the view that circulating ApoE may have anti-
atherogenic properties. Large population-based genetic studies in humans support this view.
Carriage of ε2 is associated with higher circulating concentrations of ApoE [7], lower circulat-
ing concentrations of low-density lipoprotein cholesterol (LDL-C) [8], and a lower risk of car-
diovascular disease (CVD) events [8]. In contrast, carriage of ε4 is associated with directionally
opposite changes in these markers and a higher risk of CVD. It is therefore plausible that circu-
lating concentrations of ApoE are causally associated with CVD, and, as such, ApoE could be a
useful biologicalmarker of atherosclerotic risk or a potential drug target.
To date, few studies have reported on the association of circulating ApoE concentration
with CVD events (i.e., stroke and coronary heart disease [CHD]). In one study, higher circulat-
ing concentrations of ApoE were associated with a higher risk of incident CVD [9]; this con-
trasts with the inverse association that might be expected from animal and prior human
studies. In the same population setting, a related study with a focus on stroke also found an
increase in ApoE level associated with an increased risk of stroke [10]. A third study, the largest
(total n = 2,951), also demonstrated an increase in CVDwith ApoE level; however, this increase
was limited to a subgroup of women with high high-density lipoprotein cholesterol (HDL-C)
levels [11]. These findings require replication for a number of reasons. First, two of these stud-
ies were focussed, by design, on those aged 85 y and above. Results may not apply in younger
Circulating ApoE and CVD Risk
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individuals, particularly as there is evidence of an age-dependent decline in the prevalence of
individuals with the ε4/ε4 genotype [12], who also have lower circulating concentrations of
ApoE. Second, each study was small, with few CVD outcomes (68, 54 [strokes in stroke only
study], and 156 in the three studies, respectively). Third, the ApoE-CVD associations found in
these studies were adjusted for varying risk factors, but the adjustments were not uniform
throughout. Lastly, initial reports of any association often yield an inflated effect estimate. This
phenomenon, known as the Proteus effect or winner’s curse [13], prompts the need for replica-
tion.We therefore aimed to examine the association of ApoE concentration with CVD events
in three new studies of ~10,000 middle-aged individuals in total, with a wider range of mea-
sures of cardiovascular risk factors and 1,413 CVD events.
Methods
Studies
Study details are described in detail elsewhere, but in brief; the Northwick Park Heart Study II
(NPHSII) [14] is a prospective study that recruited 3,012 men from nine general practices
across the UK with 15 y follow-up. All participants were free of CVD at the time of recruit-
ment. Median follow-up from time of ApoE measurement was 9.9 y. There were 205 CHD
events, including 136 acute myocardial infarctions (MIs), of which 50 were fatal, 65 involved
coronary revascularisations, and four were silent MIs. There were 79 strokes (35 fatal). Sixteen
individuals had both CHD and stroke events. In total there were 268 CVD events.
The English Longitudinal Study of Ageing (ELSA) [15] is a prospective study of household
participants aged 50 y and over and resident in England. ELSA participants were recruited from
respondents of the annual Health Survey for England in 1998, 1999, and 2001. In ELSA, ApoE
measurement was in wave 2 (2004–2005), and participants were asked if a doctor had diagnosed
MI and stroke at waves 3 (2006–2007), 4 (2008–2009), and 5 (2010–2011), a mean of 5.4 y from
wave 2. Mortality and follow-up was available through the National Health ServiceCentral Reg-
istry until 31 January 2010. Registration of death within 5 d is a legal requirement in England, so
participants not registered can be assumed to be alive. Death certificateswere coded using the
tenth revision of the International Classification of Disease, and those categorised as CVDwere
extracted.During this period there were 165 MIs, of which 65 were fatal; 170 strokes, of which
40 were fatal; and 12 individuals with both diagnoses. In total, there were 323 CVD events.
The Anglo-ScandinavianCardiac Outcomes Trial (ASCOT) [16] is a randomised clinical
trial of blood-pressure- and lipid-lowering treatment in the prevention of CVD in individuals
at high cardiovascular risk. A 1:1 nested case-control sample of 1,666 individuals matched for
age, sex, and country of origin was used for this study. The primary endpoint of the study was
combined non-fatal MI (including silent MI) and fatal CHD. Secondary endpoints included
all-causemortality, total stroke, all coronary events, total cardiovascular events and procedures,
cardiovascularmortality, and non-fatal and fatal heart failure. Here, only CHD cases were
included, where ascertainment was at clinical follow-up. Certifiedcauses of death were sought,
and, when available, national registries were used to find information on patients who did not
return for their final visits. Endpoints were submitted and adjudicated by the ASCOT end-
points committee, the members of which were unaware of treatment assignment.
The analyses in all studies were in accordance with approval from relevant research ethics com-
mittee, and all participants provided written informed consent. See STROBE statement (S1 Text).
ApoE Measurement
Circulating ApoE was measured using a nephelometricmethod on a BN II nephelometer (Sie-
mens), using a non-isoform-specificpolyclonal antibody. ApoE measures from NPHSII were
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made in citrated plasma taken at the fourth annual visit and were taken after a light breakfast.
ELSA and ASCOTmeasures were made in serum. Samples used in ELSA were taken at wave 2.
Most participants were fasted; those over age of 70 y (35%) and those with diabetes (7.2%)
were not asked to fast (total 35.8% of ELSA participants), althoughmost were seen prior to eat-
ing breakfast. In ASCOT, samples were taken at randomisation in the fasted state. Samples
used for all measures were taken at a time prior to any CVD events. Differences in concentra-
tion dependent on whether plasma or serumwas used for ApoE measurement were overcome
at the analysis stage by standardising measures of ApoE.
APOE Genotyping
The ELSA and NPHSII studies provided information on the APOE SNPs rs7412 and rs429358,
which were used to reconstruct the ε2/ε2, ε2/ε3 ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4 haplotypes.
Genotyping in NPHSII was carried out using Taqman (Applied Biosciences), and genotyping
in ELSA was based on KASP chemistry at LGC Genomics.
Definition of Cardiovascular Events
CHD events were defined as fatal or non-fatal MI, angiographic evidence of coronary athero-
sclerosis, or CHD events that required intervention or where individuals underwent coronary
artery bypass grafting. Stroke was defined as fatal or non-fatal; the definition encompassed
both ischaemic and haemorrhagic stroke. Total CVDwas a composite of CHD and stroke
cases and was defined as fatal or non-fatal. Specific definitions are given in primary study
reports. Comparison between definitions was carried out in order to ensure that these could be
pooled for meta-analysis.
Statistical Analysis
Statistical analysis was carried out according to a prespecified analysis plan (S2 Text). Non-
normally distributed continuous variables were logarithmically transformed. For these vari-
ables we report geometricmeans with approximate standard deviations (SDs). Differences
between case-control groups were tested by unpaired t-test or ANOVA, and differences in the
distributions of categorical variables were assessed by the χ2 test. Patients with missing data
were not included in the analysis. ApoE was in addition standardised, that is, rescaled to have a
mean of 0 and SD of 1, to overcome any difference between sample types (e.g., serum versus
plasma) across studies.
Association of ApoE with other circulatingmarkers. Bivariate associations of ApoE with
markers measured in each study were evaluated using Pearson correlation coefficients. Partial
correlations were obtained after adjusting for age and gender. In order to investigate the shape
of associations of ApoE with other circulatingmarkers, the geometricmean of log-transformed
ApoE (with 95% CI) for each decile of the associatedmarker was calculated and plotted sepa-
rately for males and females. Only the ELSA data were used to derive these measures, as infor-
mation on the widest range of measures was available from this study in both males and
females, and these data are most representative of the shape of associations in the general pop-
ulation. NPHSII included only men, who are at higher risk of CVD than women, and ASCOT
by design recruited individuals at high risk of CVD. Inclusion of both of these studies may
inflate any associations of CVD biomarkers with circulating concentrations of ApoE. Reporting
is therefore restricted to the most representative group.
Association of circulating ApoE and cardiovascularevents. Multiple logistic Cox regres-
sion and Kaplan-Meier approaches were used to assess the association of ApoE concentration
and CVD events. The primary outcome was total CVD, and secondary outcomes were fatal,
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non-fatal, and total CHD; fatal, non-fatal, and total stroke; and fatal and non-fatal CVD. Odds
ratios (ORs) for all outcomes (fatal, non-fatal, and total CHD; fatal, non-fatal, and total stroke;
fatal, non-fatal, and total CVD) and their corresponding 95% CIs were calculated using multi-
ple conditional logistic regression models in ASCOT, accounting for the matching variables of
age, sex, and country of origin and the treatment group to which individuals were randomised.
Interaction betweenApoE and randomised group was checked. Hazard ratios (HRs) with cor-
responding 95% CIs were calculated in the prospective studies using Cox regression models.
ORs and HRs were reported in two ways: first, by SD change in ApoE concentration and, sec-
ond, by tertile of ApoE concentration. Unadjusted ORs and HRs were calculated first (model
1), followed by values adjusted for total cholesterol, HDL-C, smoking, systolic blood pressure,
type 2 diabetes, age, and sex (i.e., Framingham risk variables; model 2) An additional model
adjusting for LDL-C was performed (model 3), given the observedgenetic association of APOE
with circulating LDL-C. For NPHSII, estimates were additionally adjusted by recruitment cen-
tre. Data from all studies were then pooled using random effectsmeta-analysis, weighting the
effect size in individual studies by the inverse of the variance and assessing heterogeneity using
the DerSimonian and LairdQ test, quantified using the I2 statistic. Where time-to-event data
were available, Kaplan-Meier analyses were carried out, stratifying by concentration of circulat-
ing ApoE in individuals with the baseline ε3ε3 genotype. These analyses were restricted to
NPHSII. All data analysis was carried out using Stata version 12 (StataCorp).
Association of APOE genotypeswith cardiovasculardisease and circulating lipid mark-
ers. Haplotype associations of APOE were carried out using the common ε3/ε3 as the refer-
ence genotype. The association of APOE with circulating ApoE and other lipids was examined
and the association of APOEwith CVDwas explored using Cox or logistic regression models.
Results
Studies contributed to the analyses in different ways, summarised in S1 Table.
Baseline Study Population Characteristics
A total of 9,587 individuals (1,642 from ASCOT, 5,389 from ELSA, and 2,556 from NPHSII)
for whommeasures of ApoE were available were included from all three studies. Baseline char-
acteristics are shown in Table 1. Variables that were loge transformed included ApoE, triglycer-
ides, ferritin, fibrinogen, C-reactive protein (CRP), glucose, and bodymass index. Of the 9,587
individuals with ApoE measures included in the study, 1,152 had missing data on one or more
of the Framingham variables included in model 2. The proportion of missing data was 11.8%
for ELSA, 1.6% for ASCOT, and 19.2% for NPHSII.
Cross-Sectional Associations of ApoE with Cardiovascular Risk Factors
and Other Variables
Bivariate associations of log-transformedApoE with other risk factors were assessed in the two
population-based studies ELSA and NPHSII (Table 2). Significant associations were observed
with a number of cardiovascular risk factors, including systolic and diastolic blood pressure;
total cholesterol, LDL-C, HDL-C, and triglycerides; and bodymass index (Figs 1–3; Table 2).
ApoE was also significantly associated with ApoB (correlation coefficient 0.174, p< 0.001) and
lipoprotein(a) (correlation coefficient−0.12, p< 0.001) in NPHSII, where these measures were
available, but not with ApoA1 (correlation coefficient 0.02, p = 0.46). In addition, circulating
ApoE was significantly associated with markers of inflammation including CRP (measured in
ELSA and NPHSII, correlation coefficient 0.11 and 0.13, respectively, p< 0.001 for both), ferri-
tin (ELSA only, correlation coefficient 0.07, p< 0.001), and, to a lesser extent, fibrinogen
Circulating ApoE and CVD Risk
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(correlation coefficient 0.05, p< 0.001, in ELSA, and 0.01, p = 0.52, in NPHSII) (Figs 4 and 5;
Table 2). There were no significant differences following adjustment for age or gender.
Association of ApoE Concentrations and Cardiovascular Disease during
Follow-Up
There were no statistically significant differences in circulating concentrations of ApoE
betweenCVD cases and controls for all three studies (Table 3). There was no association of
ApoE concentration either per SD increase or by tertile with CVD, with no additional evidence
of a trend of association across tertiles (Table 4). There was no significant association between
ApoE concentration and CVD in individual studies (Table 4) or when estimates were pooled
using random effectsmeta-analysis (OR 1.02, 95% CI 0.96, 1.09) or after adjustment (Framing-
ham-adjusted OR 0.97, 95% CI 0.82, 1.15) (Fig 6). Adjustment for LDL-C alone also did not
impact the overall association (OR 1.04, 95% CI 0.96, 1.13). When CHD (all CHD, fatal and
non-fatal) and stroke (all stroke, fatal and non-fatal) endpoints were assessed separately across
all three studies, there was no significant association of circulating concentration of ApoE with
either outcome (Fig 6; S2 Table). For the crude associations, analysis of ApoE quintiles and
CVD risk was carried out and a quadratic model was fitted following peer review to confirm
the absence of a U-shaped association as an explanation of a null effect (S3 Table).
Table 1. Baseline characteristics of studies included.
Characteristic NPHSII (n = 2,556) ASCOT (n = 1,642) ELSA (n = 5,389)
Age (y) 59.2 (3.3) 63.2 (8.3) 65.5 (9.3)
Sex (male) 100% 85.9% 44.4%
Current smokers 27.4% 33.5% 14.1%
Systolic blood pressure (mm Hg) 133.4 (18.1) 164.7 (17.7) 135.2 (18.7)
Diastolic blood pressure (mm Hg) 81.8 (10.8) 95.2 (10.2) 75.7 (10.9)
Total cholesterol (mmol/l) 5.63 (0.97) 5.94 (1.05) 6.00 (1.17)
High-density lipoprotein cholesterol (mmol/l) 1.72 (0.59) 1.26 (0.34) 1.54 (0.39)
Low-density lipoprotein cholesterol (mmol/l) 3.08 (1.01) 3.85 (0.93) 3.66 (0.97)
Triglycerides (mmol/l)* 1.81 (0.93) 1.65 (0.80) 1.57 (0.81) (n = 5,386)
Apolipoprotein E (mg/l)* 34.9 (11.0) 49.4 (15.4) 39.4 (12.1)
Apolipoprotein A (g/l) 1.64 (0.32) — —
Apolipoprotein B (g/l) 0.86 (0.24) — —
Lipoprotein(a) (mg/dl) 8.1 (11.6) — —
Diabetes 2.1% 26.0% 7.2%
Glucose (mmol/l)* — 6.05 (1.62) (n = 1,480) 4.95 (0.72)
Body mass index (kg/m2)* 26.4 (3.5) 28.4 (4.0) 27.4 (4.5)
Waist-to-hip ratio — — 0.89 (0.08)
C-reactive protein (mg/dl)* 2.38 (2.44) — 2.02 (2.24)
Haemoglobin (g/dl) — — 14.3 (1.4)
Ferritin (ng/ml)* — — 86.9 (72.4)
Fibrinogen (g/l)* 2.88 (0.56) — 3.13 (0.68)
Data are presented as mean (SD) or percent. Dashes indicate missing variables in the given dataset.
*Log transformed; geometric means and approximate SDs are presented.
ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; ELSA, English Longitudinal Study of Ageing; NPHSII, Northwick Park Heart Study II; SD, standard
deviation.
doi:10.1371/journal.pmed.1002146.t001
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In an exploratory analysis restricted to the sub-sample of individuals from NPHSII with the
ε3ε3 genotype, we conducted a time-to-event analysis by tertile of ApoE concentration to over-
come any isoform-specific effect. The Kaplan-Meier curves showed no major differences in
incidence of CVD events according to ApoE concentration (Fig 7).
Association of APOE Genotypes with Cardiovascular Disease and
Circulating Lipid Markers
Levels of circulating lipids—including total, LDL-, and HDL-C and triglycerides—andApoE in
the APOE genotype groups were as predicted from previous studies (S4 Table). CVD events
have previously been shown to be associated with APOE genotype. Genotype was available in
NPHSII and ELSA, and this genotypic effect is replicated on a smaller scale (S5 Table).
Discussion
Summary of Main Findings
We have described the molecular epidemiology of circulating ApoE in a large study of middle-
aged individuals that was population-based, in contrast to previous studies, which have focused
Table 2. Bivariate associations of circulating ApoE with measured markers in the population-based studies, ELSA and NPHSII.
Marker ELSA NPHSII
Correlation Coefficient p-Value Correlation Coefficient p-Value
Blood pressure
Systolic blood pressure (mm Hg) 0.08 <0.001 0.08 <0.001
Diastolic blood pressure (mm Hg) 0.10 <0.001 0.11 <0.001
Pulse pressure (mm Hg) 0.02 0.10 0.03 0.19
Circulating lipids
Total cholesterol (mmol/l) 0.46 <0.001 0.34 <0.001
High-density lipoprotein cholesterol (mmol/l) 0.16 <0.001 −0.14 <0.001
Low-density lipoprotein cholesterol (mmol/l) 0.30 <0.001 0.14 <0.001
Triglycerides (mmol/l)* 0.43 <0.001 0.46 <0.001
Apolipoprotein B (g/l) NA NA 0.13 <0.001
Apolipoprotein A1 (g/l) NA NA 0.01 0.64
Lipoprotein(a) (mg/dl) NA NA −0.11 <0.001
Haemotological markers
Haemoglobin (g/dl) 0.04 <0.001 NA NA
Ferritin (ng/ml)* 0.07 <0.001 NA NA
Fibrinogen (g/l)* 0.05 <0.001 0.01 0.52
Inflammatory markers
C-reactive protein (mg/l)* 0.11 <0.001 0.13 <0.001
Glucose and anthropometric measures
Fasting glucose (mmol/l)* −0.00 0.87 NA NA
Body mass index (kg/m2)* 0.12 <0.001 0.19 <0.001
Waist-to-hip ratio −0.02 0.18 NA NA
Lifestyle measures
Current smoking 0.03 0.01 −0.10 0.65
No differences were observed when analyses were further adjusted for age and gender.
*Log transformed.
ELSA, English Longitudinal Study of Ageing; NA, not available; NPHSII, Northwick Park Heart Study II.
doi:10.1371/journal.pmed.1002146.t002
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on ApoE concentrations in related individuals [7]. We have confirmedhere that circulating
ApoE concentration is associated with the levels of major circulating lipids and lipoproteins
including total cholesterol, LDL-C, and HDL-C as well as triglycerides; this finding is consis-
tent with published findings [7]. We further investigated the association of circulating ApoE
concentration and CVD risk in ~10,000 individuals including 1,413 CVD cases. In contrast to
prior reports [9–11], we found no association betweenApoE concentration and CVD events,
either when expressed as an OR per SD change of ApoE concentration or when examined by
tertile of ApoE concentration or by subtype of CVD.
Discrepancy with Previously Published Studies
The lack of an association between circulating ApoE and CVD contrasts with other studies
examining this association [9–11] and with an anticipated CVD protective effect of higher cir-
culating ApoE. In explaining the discrepancy of findings between the current and previous
reports, the following points are important. First, the study presented here includes individuals
who are middle-aged and are more likely to represent the major group targeted for primary
CVD prevention. Two of the previous reports included only individuals85 y old, a popula-
tion that may display a survivor bias. Moreover, it is known that the relative frequency of the
ε4ε4 genotype group, which is strongly associated with lower circulating ApoE concentrations,
declines with age [12]. Therefore, older populations are predicted to have higher circulating
Fig 1. Cross-sectional association between geometric mean of ApoE concentration and age, systolic blood
pressure, diastolic blood pressure, and pulse pressure measured in ELSA, by gender. Male (circles) and
female (square) mean log ApoE concentration was calculated for each decile of the associated variable and plotted to
visualise the shape of the association. Bars give 95% CIs.
doi:10.1371/journal.pmed.1002146.g001
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ApoE concentration (associated with enrichment for the ε2 and ε3 alleles).We did observe an
interaction between age and sex (ELSA: p for interaction< 0.001; ASCOT: p for interac-
tion = 0.02). This interaction has also been observed in other studies that measured ApoE at
scale [17]. This interaction could be due to genotypic effect or could be a result of the effect of
other unmeasured lipid intermediates that could also alter circulating levels of ApoE in men
and women. The association of ApoE with CVD risk was also replicated in PREVEND [11], a
more representative sample; however, in this study a borderline association was observed
between circulating ApoE and CVD risk in women only. Second, all CVD cases in the current
analysis are incident events, and this should largely overcome any issues of reverse causality
that can affect conclusions drawn from the retrospective case-control or cross-sectional designs
of some, but not all, previous reports [9,10]. Lastly, the size of the current analysis (1,413 cases,
five times more than the largest published study), and the replication of findings across three
different datasets, overcomes some of the limitations of prior reports on the association of cir-
culating ApoE and CVD. During the review process of this manuscript, a large (~92,000 indi-
viduals) population-based study examining the association of ApoE and CHDwas published
[18] demonstrating that circulating ApoE increases CHD risk. It is interesting to note that our
findings from all CHD (OR 1.05, 95% CI 0.98, 1.13) approach their findings (OR for ischaemic
heart disease of 1.15, 95% CI 1.04, 1.27; OR for MI of 1.16, 95% CI 1.00, 1.36), however do not
reach significance.Moreover, the association reported by Rasmussen et al. is limited to men
Fig 2. Cross-sectional association between geometric mean of ApoE concentration and total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides measured in ELSA, by gender. Male
(circles) and female (square) mean log ApoE concentration was calculated for each decile of the associated variable and plotted
to visualise the shape of the association. Bars give 95% CIs.
doi:10.1371/journal.pmed.1002146.g002
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and attenuates with the adjustment of triglycerides. Like the other published studies, Rasmus-
sen et al. did not demonstrate a convincing association with ApoE, despite a greater power to
detect such an association. The findings that they report are also contrary to the biological
prior from genetic and animal studies, that higher ApoE concentration should be protective
against atherosclerotic disease.
Placing Findings in the Context of Known Genetics of APOE and
Biological Functions of ApoE
The observation that individuals with very low or completely absent circulating ApoE develop
early atherosclerosis, and that this has a genetic basis [5], has been influential in the develop-
ment of hypotheses on the role of ApoE in atherosclerosis. The largest genetic study investigat-
ing the association of APOEmutations with CVD support this hypothesis [8]. For the ε2ε2
(associated with higher circulating ApoE) versus ε3ε3 comparison, Bennet et al. [8] demon-
strated an OR of 0.80 (95% CI 0.70, 0.90) for CVD. Our data do not reach significance; for the
same comparison, we have 30% power to detect an OR of this size at a 5% significance level
using 377 cases and 4,709 controls, but the trend of the effect is similar (S5 Table). Human
studies have been dominated by evaluation of the relationship of APOE genotype with a range
of diseases including CVD, Alzheimer disease [19], and age-related macular degeneration [20].
Together with animal studies, these human studies have contributed to the prevailing view that
Fig 3. Cross-sectional association between geometric mean of ApoE concentration and glucose, body mass index,
and waist-to-hip ratio measured in ELSA, by gender. Male (circles) and female (square) mean log ApoE concentration was
calculated for each decile of the associated variable and plotted to visualise the shape of the association. Bars give 95% CIs.
doi:10.1371/journal.pmed.1002146.g003
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circulating ApoE is anti-atherogenic. For example, carriage of ε2 is associated with higher cir-
culating concentration of ApoE, lower LDL-C concentration, and lower risk of CVD [8]. Con-
versely, carriage of ε4 is associated with directionally opposite changes in ApoE and LDL-C
concentration and a higher risk of CVD. These findings have been interpreted as a conse-
quence of the functional differences between isoforms of ApoE, namely, lipid and receptor
binding, rather than circulating concentrations of the protein. For example, the E2 isoform
binds LDL-R and LRP1 with a reduced efficiency compared to the other isoforms (2% com-
pared to E3; E4 has affinities comparable to E3) [21,22]. This reduced binding efficiencyhas
been thought to result in up-regulation of expression of LDL-R and LRP1, with the consequent
effect of increasing clearance and lowering circulating concentrations of pro-atherogenic
VLDLs, chylomicrons, and their remnants. E2 as well as E3 preferentially bind to small phos-
pholipid-rich HDL-C particles, in contrast to E4, which binds larger pro-atherogenic triglycer-
ide-rich particles [23]. Binding with HDL-C supports an additional role of E2 in reverse
cholesterol transport, as ApoE acts as a ligand for high-density-lipoprotein-mediated choles-
terol delivery to the liver. However, the present study indicates a null association of ApoE con-
centration with CVD risk overall and in analyses restricted to individuals with the ε3/ε3
genotype.
One of the functional consequences of the reduced binding to LDL-R and LRP1 of E2 could
be higher detectable concentrations of ApoE. This has been interpreted as higher levels of cir-
culating ApoE being protective. However, a higher detectable concentration of ApoE could be
Fig 4. Cross-sectional association between geometric mean of ApoE concentration and haemoglobin, ferritin, and
fibrinogen measured in ELSA, by gender. Male (circles) and female (square) mean log ApoE concentration was calculated for
each decile of the associated variable and plotted to visualise the shape of the association. Bars give 95% CIs.
doi:10.1371/journal.pmed.1002146.g004
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a paradoxical increase as a consequence of the genetic point mutation rather than being causal
in itself. One way in which ApoE concentration might be useful in CVD prediction is with iso-
form-specificmeasures. The predictive utility of isoforms could then be tested in large popula-
tions. However, it should be borne in mind that, given the distribution of cases and controls
amongst genotype groups, most cases will occur in those with circulating ApoE3, as these indi-
viduals make up the majority of the population (S1 Fig). Most cases of CVD will therefore have
circulating concentrations of ApoE within the normal range (i.e., within 2 SDs of the popula-
tion mean). However, that does not preclude ApoE being a useful target for CVD; rather, any
drug would need to recapitulate the pattern of lipids seen with circulating E2. Such a drug
could be useful in individuals with any genotype.
Two other courses of investigation to more precisely defining the role of ApoE in health and
disease are now necessary. First, the view that APOE confers disease risk (and/or protection)
mediated through LDL-C may be over simplistic. Functional studies of all isoforms indicate
the importance of ApoE in the clearance of other potentially atherogenic lipid particles includ-
ing VLDLs, chylomicrons, and their remnants. To date, studies in small samples (~200
Fig 5. Cross-sectional association between geometric mean of ApoE concentration and C-reactive
protein measured in ELSA, by gender. Male (circles) and female (square) mean log ApoE concentration
was calculated for each decile of the associated variable and plotted to visualise the shape of the
association. Bars give 95% CIs.
doi:10.1371/journal.pmed.1002146.g005
Table 3. ApoE concentrations in individuals who later developed cardiovascular disease by case/
control status in all three studies.




ASCOT 49.01 (15.67) [820] 49.83 (15.12) [822] 0.28
ELSA 39.34 (12.03) [5,066] 39.47 (12.71) [323] 0.85
NPHSII 34.82 (10.98) [2,288] 35.98 (10.68) [268] 0.11
doi:10.1371/journal.pmed.1002146.t003
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Table 4. Summary estimates for the association of log ApoE concentration with cardiovascular events from the three studies.
ApoE Concentration Model 1 Model 2 Model 3
OR or HR (95% CI) p-Value OR or HR (95% CI) p-Value OR or HR (95% CI) p-Value
ASCOT
Per SD increase in log ApoE 0.99 (0.89, 1.10) 0.89 0.83 (0.74, 0.94) 0.003 0.96 (0.85, 1.08) 0.52
Tertile 1 Ref Ref Ref
Tertile 2 1.07 (0.84, 1.36) 0.58 0.89 (0.69, 1.15) 0.05 1.23 (0.93, 1.62) 0.79
Tertile 3 1.07 (0.83, 1.39) 0.74 (0.56, 1.00) 1.03 (0.77, 1.38)
ELSA
Per SD increase in log ApoE 1.01 (0.90, 1.13) 0.85 1.08 (0.94, 1.25) 0.27 1.08 (0.95, 1.22) 0.23
Tertile 1 Ref Ref Ref
Tertile 2 0.97 (0.74, 1.29) 0.65 1.04 (0.75, 1.44) 0.32 1.11 (0.84, 1.48) 0.12
Tertile 3 1.07 (0.81, 1.39) 1.19 (0.85, 1.66) 1.25 (0.94, 1.66)
NPHSII
Per SD increase in log ApoE 1.08 (0.96, 1.22) 0.20 1.03 (0.90, 1.19) 0.66 1.09 (0.95, 1.25) 0.21
Tertile 1 Ref Ref Ref
Tertile 2 1.24 (0.92, 1.68) 0.23 1.53 (1.07, 2.17) 0.51 1.41 (1.00, 1.99) 0.16
Tertile 3 1.21 (0.89, 1.63) 1.16 (0.81, 1.68) 1.30 (0.92, 1.84)
Estimates are presented as the odds of cardiovascular disease per SD increase in ApoE concentration and as the OR per tertile of ApoE, where the
reference group is tertile 1. p-Values represent a test of trend across ApoE tertiles. Model 1 is unadjusted; model 2 is Framingham adjusted; model 3 is
LDL-C adjusted; ORs are reported for the ASCOT case-control subset and ELSA, and HRs are reported for the prospective NPHSII.
ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; ELSA, English Longitudinal Study of Ageing; HR, hazard ratio; NPHSII, Northwick Park Heart Study
II; OR, odds ratio; SD, standard deviation.
doi:10.1371/journal.pmed.1002146.t004
Fig 6. Meta-analysis of association of ApoE level with coronary heart disease and stroke. Adjusted (for Framingham variables) and
unadjusted summaries are given separately. ORs represent per SD change of ApoE. Numbers of events and total numbers included in
each analysis are given in S4 Table. CHD, coronary heart disease; CVD, cardiovascular disease; LDL-C, low-density lipoprotein
cholesterol; OR, odds ratio; SD, standard deviation.
doi:10.1371/journal.pmed.1002146.g006
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individuals) [24] have indicated that there is indeed a differential effect of APOE genotype on
circulating lipids other than the “traditionally” measured LDL-C, HDL-C, and triglycerides.
Investigation of other lipid intermediates and their association with APOE now requires a pop-
ulation-level effort and may prove to be more fruitful than ApoE with respect to predictive util-
ity for CVD. Measurement of these lipid intermediates is now possible in a time- and cost-
efficient way using high-throughput mass spectrometry and nuclear magnetic resonance plat-
forms. Second, the view that the genetic variation in the APOE locus that influences CVD risk
is limited to the ε2/ε3/ε4 haplotype is also being challenged. Genetic studies using genome-
wide [25] and gene-centric SNP arrays [26] implicate genes flankingAPOE, including BCL3,
PVRL2, TOMM40, and APOC1-C4-C2, rather than APOE itself in regulation of circulating
lipid concentrations, in particular LDL-C, as well as additional variants within the APOE gene.
The strength of these associations is greater than that with SNPs in APOE alone. Limitations of
some of these studies include the fact that both SNPs that determine the ε2/ε 3/ε 4 haplotype
(rs429358 and rs7412) are not included on all SNP arrays or are not well imputed and therefore
have not been identified as signals in such analyses. However, even where these SNPs are
directly typed and included in analyses, the strength of the association with circulating lipids is
Fig 7. Kaplan-Meier plot for tertiles of ApoE concentration in individuals with ε3ε3 genotype. This analysis was conducted to
overcome any effect of isoform or structural change in the circulating protein. High concentrations are indicated in blue, intermediate in red,
and low in green. Precise time-to-event measures are available in NPHSII, and therefore analyses are restricted to this study. There is a
marginally statistically significant relationship between ApoE concentration and time to CVD event; however, given that this analysis is
restricted to one study, which included only men, it has to be interpreted with caution. CVD, cardiovascular disease.
doi:10.1371/journal.pmed.1002146.g007
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greater from the flanking regions [26]. Results from large genome-wide association studies and
consortia data can now be used to inform further functional and molecular analyses, in order
to truly assess the effect of APOE and circulating ApoE on disease risk. This is not only of inter-
est in CVD, but also in other diseases of ageing including Alzheimer disease, where the risk
conferred by APOE ε4 is>5-fold greater than that seen in CVD, and age-related macular
degeneration, where, in contrast to Alzheimer disease and CVD, ε2 confers an increase in risk
of disease and ε4 confers a protective effect.
Limitations of This Study
It is important to address some limitations of this study. First, the assay used here is commer-
cial, using a polyclonal antibody. It does not discriminate between isoforms of circulating
ApoE. However, the pattern of observinghigher circulating concentrations with carriage of E2
and lower concentrations with carriage of E4 is preserved and consistent with other studies.
We are therefore confident that the concentrations measured are a reflection of the underlying
genotype. Second, although the sample size is larger than that of previously reported studies,
compared to studies that reliably estimate the risk of a marker for a disease, it is still moderate.
These studies require further replication in order to more precisely delineate the direction and
magnitude of the effect. Third, we are unable to differentiate between ischaemic and haemor-
rhagic stroke in the presented results, but, given that haemorrhagic stroke represents 10%–15%
of stroke cases in the general population (https://www.strokeaudit.org) and a total of 249
strokes are included, it is doubtful that this would bias the results. Finally, samples that were
used for measurement were taken before incident events, and the median time before an event
across all included studies was 5.5 y. This time between sampling and event could be one expla-
nation of an attenuated effect. However, the follow-up time is comparable to that of other pub-
lished studies that do show a relationship of circulating ApoE with CVD, even with small
sample sizes. One way in which this variability of ApoE could be overcome is to construct and
then adjust for regression dilution ratios. Ratios are based on regression of serial measures of
ApoE on baseline levels with any additional and necessary adjustments. However, serial mea-
sures were available neither in the studies presented here nor in the current ApoE literature,
and these analyses will be possible only once these data emerge. Exploratory analysis applying
to ApoE regression dilution ratios calculated by the CRP-CHD Genetics Consortium for
another blood-basedbiomarker, CRP (where the regression dilution ratio adjusted for age and
sex was 0.57, 95% CI 0.51, 0.64) [27], indicated that the effect of regression to the mean is
unlikely to have a major effect on the observed association, with the odds of CVD for a 1-SD
increase in ApoE increasing from 1.02 to 1.035. These analyses were carried out following edi-
torial comments during the review process.
In order to more precisely link genetic variation in the APOE gene locus to disease and bio-
markers, finer resolution of the genetic variation in this region is required. This can be achieved
through next-generation sequencing or imputation against broad (1000 Genomes) and deep
marker panels. Integrating this information with circulating concentrations of ApoE and a
range of other biomarkers, and specifically lipid intermediates, may clarify the link between
genotype, circulating ApoE, and CVD and other diseases. This will inform the clinical utility of
tests based on measurement of either genotype or circulating ApoE, or of indeed targeting
ApoE with new therapeutic agents.
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